Drug development to protozoan diseases

Open Medicinal Chemistry Journal

Volumn 5, Issue SPEC. ISSUE 1, 2011, Pages 1-3

  Monzote, Lianet ^a   Siddiq, Afshan ^b  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Anti infective; Anti protozoan; Drugs

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; ARTEMISIN; BENZNIDAZOLE; CHLOROQUINE; DILOXANIDE; EFLORNITHINE; MELARSOPROL; METRONIDAZOLE; MILTEFOSINE; NIFURTIMOX; PENTAMIDINE; PYRIMETHAMINE; SULFONAMIDE; SURAMIN;

AFRICAN TRYPANOSOMIASIS; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHAGAS DISEASE; DRUG SAFETY; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION RATE; LEISHMANIASIS; MALARIA; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTOZOAL INFECTION; TOXOPLASMOSIS; TRICHOMONIASIS; TRYPANOSOMA GAMBIENSE;

EID: 80155186278     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501105010001     Document Type: Article

References (15)

1. Fennell, B.J.; Naughton, J.A.; Barlow, J.; Brennan, G.; Fairweather, I.; Hoey, E.; McFerran, N.; Trudgett, A.; Bell, A. Microtubules as antiparasitic drug targets. Expert Opin. Drug Discov., 2008, 3, 501-518.
2. Pink, R.; Hudson, A.; Mouriés, M.A.; Bendig, M. Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov., 2005, 4, 727-740.
3. Tekwani, B.L.; Walker, L.A. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr. Opin. Infect. Dis., 2006, 19, 623-631.
4. Watkins, B.M. Drugs for the control of parasitic diseases: current status and development. Trends Parasitol., 2003, 19, 477-478.
5. Dupouy-Camet, J. New drugs for the treatment of human parasitic protozoa. Parasitologia, 2004, 46, 81-84.
6. Cooper, R.A.; Carucci, D.J. Proteomic approaches to studying drug targets and resistance in Plasmodium. Curr. Drug Targets Infect. Disord., 2004, 4, 41-51.
7. Aparicio, P.; Rodríguez, E.; Gárate, T.; Molina, R.; Soto, A.; Alvar, J. Terapêutica antiparasitária. Enferm. Infecc. Microbiol. Clin., 2003, 21, 579-594.
8. Cowman, A.F.; Crabb, B.S. Functional genomics: identifying drug targets for parasitic diseases. Trends Parasitol., 2003, 19, 538-543.
9. Bleicher, K.H.; Bohm, H.J.; Muller, K.; Alanine, A.I. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov., 2003, 2, 369-378.
10. Kissinger, J.C. A tale of three genomes: the kinetoplastids have arrived. Trends Parasitol., 2006, 22, 240-243.
11. Morales, A.; Rodríguez-Borgues, J.E.; García-Mera, X.; Fernández, F.; Cordeiro, M.N. Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set. J. Med. Chem., 2007, 50, 1537-1545.
12. Kozikowski AP, Roth B, Tropsha A. Why academic drug discovery makes sense. Science, 2006, 313, 1235-1236.
13. Nwaka, S.; Hudson, A. Innovative lead discovery strategies for tropical diseases. Nat. Rev., 2006, 5, 941-954.
14. Nwaka S, Ridley RG. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nature Rev. Drug Dis., 2003, 2, 919-928.
15. Na- Bangchang, K.; Karbwang, J. Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development. Fund. Clin. Pharmacol., 2009, 23, 387-409.